PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-1.06%
Cash & equivalents declining -1.06% while Healthcare shows 0.00% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-1.06%
Cash + STI yoy growth 1.25-1.5x the Healthcare median of -0.80%. Mohnish Pabrai might see a strategic surplus if short-term returns make sense.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.06%
0.75-0.9x the Healthcare median of -1.25%. John Neff wonders if the firm invests less in working capital or sales growth is slower.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.06%
1.25-1.5x Healthcare median of -0.80%. Mohnish Pabrai might see above-average growth. Check if financed sensibly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.54%
Above 1.5x Healthcare median of 0.00%. Jim Chanos suspects potential working capital strain.
11.50%
Above 1.5x Healthcare median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
11.50%
Below half Healthcare median of -0.14%. Joel Greenblatt sees more conservative long-term liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
5.06%
Above 1.5x Healthcare median of 0.00%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
-1.40%
Below half Healthcare median of 0.00%. Jim Chanos suspects poor profitability or large dividend drains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.28%
≥ 1.5x Healthcare median of -0.85%. Joel Greenblatt sees stronger equity growth vs. peers.
-1.06%
1.25-1.5x Healthcare median of -0.72%. Mohnish Pabrai notes above-average growth in liabilities + equity.
No Data
No Data available this quarter, please select a different quarter.
11.50%
Above 1.5x Healthcare median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
12.22%
Above 1.5x Healthcare median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.